November 2021 OSE Immunotherapeutics Presented the First Positive Preclinical Efficacy Data on CLEC-1
October 2021 OSE Immunotherapeutics to Present New Preclinical Data at Upcoming Bispecific Antibody and Immunology Conferences
October 2021 Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of BI 765063
October 2021 OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial